Do Institutional Investors Love Diplomat Pharmacy (NYSE:DPLO)?

Diplomat Pharmacy, Inc. (NYSE:DPLO) Logo

Sentiment for Diplomat Pharmacy (NYSE:DPLO)

Diplomat Pharmacy (NYSE:DPLO) institutional sentiment increased to 1.16 in Q1 2019. Its up 0.10, from 1.06 in 2018Q4. The ratio improved, as 67 institutional investors opened new and increased positions, while 58 reduced and sold stock positions in Diplomat Pharmacy. The institutional investors in our partner’s database now have: 58.33 million shares, down from 63.85 million shares in 2018Q4. Also, the number of institutional investors holding Diplomat Pharmacy in their top 10 positions decreased from 1 to 0 for a decrease of 1. Sold All: 27 Reduced: 31 Increased: 44 New Position: 23.

Diplomat Pharmacy, Inc. operates as an independent specialty pharmacy in the United States. The company has market cap of $441.56 million. The firm stocks, dispenses, and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers. It currently has negative earnings. It also provides specialty infusion pharmacy, patient care coordination, clinical, compliance and persistency program, patient financial assistance, specialty pharmacy training/consulting, benefits investigation, prior authorization, risk evaluation and medication strategy, retail specialty, and hub services, as well as clinical and administrative support services to hospitals and health systems.

The stock decreased 2.64% or $0.16 during the last trading session, reaching $5.91. About 785,965 shares traded. Diplomat Pharmacy, Inc. (NYSE:DPLO) has declined 77.45% since July 14, 2018 and is downtrending. It has underperformed by 81.88% the S&P500.

Analysts await Diplomat Pharmacy, Inc. (NYSE:DPLO) to report earnings on August, 5. They expect $-0.19 EPS, down 211.76 % or $0.36 from last year’s $0.17 per share. After $-0.19 actual EPS reported by Diplomat Pharmacy, Inc. for the previous quarter, Wall Street now forecasts 0.00 % EPS growth.

Armistice Capital Llc holds 0.95% of its portfolio in Diplomat Pharmacy, Inc. for 3.00 million shares. Rhenman & Partners Asset Management Ab owns 1.20 million shares or 0.82% of their US portfolio. Moreover, S&T Bank Pa has 0.72% invested in the company for 551,620 shares. The Connecticut-based Matarin Capital Management Llc has invested 0.29% in the stock. Advisory Services Network Llc, a Georgia-based fund reported 598,802 shares.

Diplomat Pharmacy, Inc. (NYSE:DPLO) Ratings Coverage

Ratings analysis reveals 17% of Diplomat Pharmacy’s analysts are positive. Out of 6 Wall Street analysts rating Diplomat Pharmacy, 1 give it “Buy”, 0 “Sell” rating, while 5 recommend “Hold”. The lowest target is $6 while the high is $8. The stock’s average target of $6.86 is 16.07% above today’s ($5.91) share price. DPLO was included in 17 notes of analysts from February 22, 2019. Credit Suisse maintained the shares of DPLO in report on Tuesday, April 2 with “Neutral” rating. On Tuesday, March 19 the stock rating was maintained by Wells Fargo with “Hold”. J.P. Morgan maintained Diplomat Pharmacy, Inc. (NYSE:DPLO) rating on Monday, March 18. J.P. Morgan has “Hold” rating and $7 target. The stock of Diplomat Pharmacy, Inc. (NYSE:DPLO) has “Hold” rating given on Friday, February 22 by Mizuho. Mizuho maintained it with “Hold” rating and $6 target in Monday, March 18 report. Barclays Capital maintained the shares of DPLO in report on Monday, February 25 with “Buy” rating. The stock has “Neutral” rating by JP Morgan on Monday, March 18.

More notable recent Diplomat Pharmacy, Inc. (NYSE:DPLO) news were published by: which released: “The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of MHLD, AVP, DPLO and ARA – GlobeNewswire” on April 02, 2019, also with their article: “DPLO CLASS ACTION REMINDER: Hagens Berman Reminds Diplomat Pharmacy (DPLO) of Securities Class Action, Encourages Investors to Contact the Firm – PRNewswire” published on April 15, 2019, published: “Diplomat Launches Empower Ecosystem Patient Support Digital Library – PRNewswire” on July 09, 2019. More interesting news about Diplomat Pharmacy, Inc. (NYSE:DPLO) were released by: and their article: “Diplomat Pharmacy Q1 2019 Earnings Preview – Seeking Alpha” published on May 06, 2019 as well as‘s news article titled: “Analysts React To Diplomat Pharmacy’s Q4 Earnings, Concerning Guidance – Benzinga” with publication date: March 18, 2019.

Diplomat Pharmacy, Inc. (NYSE:DPLO) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.